Microarray-powered

FastMAb®

Microarray-powered Custom Monoclonal Antibody Development & Specificity Validation

The CDI FastMAb® antibody development platform addresses the urgent need for monoclonal antibodies with unprecedented specificity to native or denatured proteins, depending on your needs.

CDI utilizes its HuProt™ Human Proteome Microarray for validating the final product – therefore your antibody will be screened for cross-reactivity against the largest collection of human proteins on a single slide, representing ~75% of the human proteome.

Be Specific. Whether you are grant-writing, publishing or manufacturing... make CDI FastMAb® part of your discovery and development success.

Details. >>

www.cdi-lab.com
FastMAb® Project Overview

FastMAb® monoclonal antibody development, production and purification, along with HuProt™ microarray specificity validation, is an approximate 8 week process. It is a milestone-driven, 4-phase process with client reporting and assessment exchanged at each step. Invoicing begins at the initiation of Phase 1 and at the completion of each phase thereafter. Milestones represent potential endpoints that depend on your project requirements or if the results-to-date fail to meet your expectations.

**Phase 1 >> Antigen and Immunization**

5-mouse immunization regimen using as little as 200 µg client-supplied protein of >80% purity or carrier-conjugated peptide. Alternatively, CDI offers assistance in antigen design and synthesis.

**Phase 2 >> Fusion and Screening**

2 top-responding animals are chosen, and immune cells are harvested for fusion with myeloma cells yielding multiple hybridomas. Supernatants from IgG-secreting clones are screened by ELISA. Client consultation.

**Phase 3 >> Sub-cloning, Expansion and Specificity Testing**

A minimum of 5 to a maximum of 30 high-quality clones are chosen and sub-cloned. Each is expanded into 24-well plates and subsequently into T-25 flasks. Supernatants are shipped for further client evaluation.

**Phase 4 >> Production and Purification**

Each clone is vialled, labeled and frozen. Samples of each are reserved for mycoplasma testing. Per client instructions, 3 select clones are placed into antibody production. The resulting antibodies are purified and evaluated with CDI HuProt™ Human Proteome Microarray, v 2.0.

**Deliverables**

Detailed specificity data and additional QA documentation are prepared and shipped to the client along with the purified antibodies and all frozen clones.

*For more information, including pricing, project initiation and additional antibody or microarray-related services, please call us at 787.806.4100 or 844-539-6296 TOLL FREE US/Canada.

Already have an antibody? CDI offers High Spec® cross-reactivity testing using the HuProt Microarray. Be Specific.